Anticancer Effect of Rosiglitazone, a PPAR-Î³ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis.

Wu, Yanqiao; Sreeharsha, Nagaraja; Sharma, Sanjay; Mishra, Anurag; Singh, Avinash Kumar; Gubbiyappa, Shiva Kumar

Wu, Yanqiao; Sreeharsha, Nagaraja; Sharma, Sanjay; Mishra, Anurag; Singh, Avinash Kumar; Gubbiyappa, Shiva Kumar.

Afiliación

Wu Y; Intensive Care Unit, People's Hospital of Ningjin County, Ningjin County, Shandong province 253400, China.
Sreeharsha N; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Sharma S; NMIMS, School of Pharmacy and Technology Management, Shirpur 425405, Maharashtra, India.
Mishra A; School of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India.
Singh AK; Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Gubbiyappa SK; School of Pharmacy, GITAM University, Hyderabad 530045, India.

ACS Omega ; 5(10): 5334-5339, 2020 Mar 17.

Article en En | MEDLINE | ID: mdl-32201822

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Omega Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google